Glaukos SVP Thurman sells $267k in GKOS stock By Investing.com

CFO Alex R. Thurman sold 2,511 shares at $106.46 on Mar 25, 2026 for $267,321 under a pre-arranged 10b5-1 plan and now directly owns 41,967 shares (including 5,230 unvested RSUs); he also received various option grants and 3,303 shares valued at $0. The FDA approved an NDA labeling supplement allowing repeat re-administration of iDose TR, expanding treatment options and supporting product momentum. Analysts raised or reiterated targets (Needham $127 Buy; Stifel $160 Buy; Piper Sandler $165 Overweight) while the company remains unprofitable with a $6.25B valuation and InvestingPro flagging the stock as overvalued versus fair value.

Analysis

A regulatory pathway that effectively converts a one-time implant sale into a re-dosing revenue stream materially changes iDose economics: lifetime revenue per patient increases, payback on salesforce deployment shortens, and inventory turns rise. Expect management to prioritize manufacturing scale and repeat-treatment training for physicians — that creates near-term capex and COGS pressure but a multi-year boost to revenue visibility if uptake follows.

Second-order winners include sterile manufacturing partners and contract manufacturers able to scale small-batch ophthalmic implants quickly; losers are single-dose drug players whose revenue per patient is fixed and who face margin compression when implants capture follow-on spend. Concentrated supplier relationships for implant housings or drug reservoirs become single points of failure — a manufacturing hiccup would amplify share volatility.

Key risks are binary coverage and reimbursement decisions and real-world durability of repeat treatments: an adverse Local Coverage Determination or slow payer uptake can reverse consensus tailwinds within 3-12 months. Insider liquidity activity plus sizeable option/grant run-rate suggests potential dilution over the 12–36 month horizon, so upside must be large enough to absorb share-count expansion.

Monitor near-term catalysts: early re-dosing utilization metrics, first CMS/LCD signals, and sequential iDose revenue growth. These three datapoints will move the stock more than incremental analyst optimism; absence of clear adoption data is the most likely path for underperformance despite bullish narrative.

Key Decisions for Investors

• Long GKOS via defined-risk call spread (ticker GKOS): buy Jan-2027 30–40% OTM call spread as a directional play on adoption; max loss = premium paid, upside ~3x if uptake and repeat-revenue thesis materialize over 12–18 months. Enter on <15% pullback to improve R/R.
• Event-hedged equity buy (ticker GKOS): accumulate up to 2% position size on a 20%+ pullback, hedged 1:1 with short exposure to a medtech ETF (IHI) to isolate company-specific adoption risk; target 18–24 month hold to capture commercialization cadence, stop-loss at 12% absolute drawdown.
• Tail protection / speculative short (ticker GKOS): buy 6–9 month OTM puts (25–35% OTM) as inexpensive insurance against an adverse LCD or supply shock; these pay well if coverage is restricted within 3–9 months and limit capital at risk to premium.
• Avoid outright long leverage into current narrative until first sequential re-dosing volumes are reported; if those metrics beat, rotate from options to stock to capture multiple expansion while monitoring dilution cadence for earnings-per-share impact.